By Amr Gohar
Washington, D.C.The U.S. House of Representatives has unanimously passed the Mikaela Naylon Give Kids A Chance Act, a major bipartisan bill aimed at accelerating treatment options for childhood cancer and rare pediatric diseases. The bill is named in memory of Mikaela Naylon, a young cancer patient who advocated for the legislation before her passing earlier this year.
Introduced by Rep. Michael McCaul (R-Texas) and supported by lawmakers from both parties, the legislation merges the Give Kids a Chance Act with the Creating Hope Reauthorization Act to strengthen pediatric drug research, expand access to modern therapies, and close longstanding gaps in treatment development for children.
A key feature of the bill is the reauthorization of the FDA Rare Pediatric Disease Priority Review Voucher (PRV) program, which incentivizes pharmaceutical companies to develop treatments for rare childhood illnesses. Since its creation in 2011, the program has issued 63 vouchers tied to at least 39 rare pediatric diseases. The new bill also authorizes the FDA to require companies to study promising drug combination therapies in children — an area where research has lagged significantly behind adult cancer treatment.
The legislation received broad bipartisan support, with lawmakers emphasizing the urgent need to accelerate pediatric cancer research and expand treatment options nationwide. Members noted that nearly 16,000 children in the United States are diagnosed with cancer each year, and that children account for up to half of all Americans living with rare diseases, yet they have far fewer approved therapies compared to adults.
Supporters say the bill brings renewed hope for families facing rare and life-threatening illnesses and marks one of the most significant steps toward improving pediatric cancer care in over a decade.
The measure now heads to the U.S. Senate, where advocates are pushing for swift approval.
Original article
Comments